# Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

> **NCT07022197** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tianjin Medical University General Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- NMO Spectrum Disorder
- Myasthenia Gravis
- Idiopathic Inflammatory Myopathies

## Interventions

- **DRUG:** BAFF-R CART

## Key facts

- **NCT ID:** NCT07022197
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-10
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07022197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07022197, "Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07022197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*